Symmetric dimethylguanidino valeric acid, a novel single biomarker of hepatic steatosis
Year: 2024
Type: article
Study design: Observational Study
Abstract: There is an unmet need for a biomarker of liver fat. We identified dimethylguanidino valeric acid (DMGV) as a circulating biomarker of liver fat. Here, we assess its two isoforms-symmetric (SDGV) and asymmetric (ADGV)-as biomarkers of steatosis. We determined plasma ADGV, SDGV, related metabolites, alanine aminotransferase (ALT), and the fatty liver index (FLI) in two cohorts and compared their diagnostic performance for liver fat detection. SDGV was the strongest predictor of moderate to severe steatosis. Changes in SDGV correlated with changes in liver fat % in a prospective cohort. In a murine model of fatty liver disease, protein levels and activity of alanine:glyoxylate aminotransferase 2 (AGXT2), which produces SDGV, were increased and coincided with elevation of SDGV concentrations. SDGV is a biomarker of liver fat and its increase in hepatic steatosis results from the upregulation of AGXT2 activity.
Source: iScience
Authors: Roman N. Rodionov, Natalia Jarzebska, Yen Chin Koay, Mengbo Li, Matthias Kuhn, Stefan R. Bornstein, Jens Martens-Lobenhoffer, Mohammad Eslam, Fei Wen Chen, Elena Rubets, Alexander G. Markov, Norbert Weiss, Andreas Birkenfeld, Peter Schwarz, Stefanie M. Bode-Böger, Nikolaos Perakakis, John F. O’Sullivan, Jacob George
Institutions: Flinders University, Flinders Medical Centre, Technische Universität Dresden, University Hospital Carl Gustav Carus, The University of Sydney, The University of Melbourne, Walter and Eliza Hall Institute of Medical Research, King's College London, German Center for Diabetes Research, Paul Langerhans Institute Dresden, Otto-von-Guericke-Universität Magdeburg, Westmead Hospital, Westmead Institute for Medical Research, St Petersburg University, Helmholtz Munich, University of Tübingen
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,150
Awards: Verbundprojekt: Initiierung des Aufbaus des Deutschen Zentrums für Diabetesforschung, Verbundpartner Eberhard-Karls-Universität Tübingen, G5156603513, Delineating the clinical and molecular heterogeneity of fatty liver disease to inform treatment, MERTK receptor tyrosine kinase: A novel therapeutic target for liver fibrosis, G5960329499, Targeting the crosstalk between metabolism and epigenetics to treat liver fibrosis, Hepatitis C infection and disease, G6972562232, G8068805097, How does dietary cholesterol induce non-alcoholic steatohepatitis?
OpenAlex ID: W4404328704